

LIPOTROPICS, OTHER PRIOR AUTHORIZATION FORM

Prior authorization guidelines for **Lipotropics, Other** and **Quantity Limits/Daily Dose Limits** are available on the DHS Pharmacy Services website at <http://www.dhs.pa.gov/provider/pharmacyservices/index.htm>.

PRIOR AUTHORIZATION REQUEST INFORMATION		PRESCRIBER INFORMATION	
<input type="checkbox"/> New request	<input type="checkbox"/> Renewal request	Total # of pages: _____	Prescriber name:
Name of office contact:		Specialty:	
Contact's phone number:		State license #:	
Facility contact/phone:		NPI:	MA Provider ID#:
BENEFICIARY INFORMATION		Street address:	
Beneficiary Name:		Suite #:	City/state/zip:
Beneficiary ID#:	DOB:	Phone:	Fax:

CLINICAL INFORMATION

Non-Preferred Medication Requested: (For Repatha and Praluent, use PCSK9 Inhibitors form. For Juxtapid or Kynamro, use Juxtapid/Kynamro form.)			
<input type="checkbox"/> Antara capsule	<input type="checkbox"/> fenofibric acid tablet	<input type="checkbox"/> niacin ER OTC capsule	<input type="checkbox"/> Tricor tablet
<input type="checkbox"/> Colestid flavored granules	<input type="checkbox"/> fenofibric acid DR capsule	<input type="checkbox"/> niacin ER Rx tablet	<input type="checkbox"/> Triglide tablet
<input type="checkbox"/> Colestid granules	<input type="checkbox"/> Fenoglide tablet	<input type="checkbox"/> Niacor tablet	<input type="checkbox"/> TriLipix DR capsule
<input type="checkbox"/> Colestid granules packet	<input type="checkbox"/> Fibracor tablet	<input type="checkbox"/> Niaspan ER tablet	<input type="checkbox"/> Vascepa capsule
<input type="checkbox"/> Colestid tablet	<input type="checkbox"/> Lipofen capsule	<input type="checkbox"/> Questran packet	<input type="checkbox"/> Welchol tablet
<input type="checkbox"/> colestipol granules	<input type="checkbox"/> Lopid tablet	<input type="checkbox"/> Questran powder	<input type="checkbox"/> Zetia tablet
<input type="checkbox"/> colestipol granules packet	<input type="checkbox"/> Lovaza capsule	<input type="checkbox"/> Questran Light powder	<input type="checkbox"/> _____
<input type="checkbox"/> fenofibrate capsule	<input type="checkbox"/> niacin OTC tablet	<input type="checkbox"/> Slo-Niacin tablet	
<input type="checkbox"/> fenofibrate tablet (40 mg & 120 mg)	<input type="checkbox"/> niacin ER OTC tablet		
Strength:	Directions:	Quantity:	Refills:
Diagnosis:		Diagnosis code (required):	
1. Which of the following preferred agents in this therapeutic class has the Beneficiary tried & failed? <u>Check all that apply.</u>			<i>Submit medical record documentation, including baseline and follow-up cholesterol panels.</i>
<input type="checkbox"/> cholestyramine, cholestyramine light, or Prevalite powder/packet	<input type="checkbox"/> gemfibrozil tablet	<input type="checkbox"/> omega-3 acid ethyl esters cap	
<input type="checkbox"/> colestipol tablet	<input type="checkbox"/> omega-3 acid ethyl esters cap	<input type="checkbox"/> Welchol powder packet	
<input type="checkbox"/> ezetimibe tablet			
<input type="checkbox"/> fenofibrate 54 mg & 160 mg tablet (generic Lofibra)			
<input type="checkbox"/> fenofibrate <u>nanocrystal</u> 48 mg & 145 mg tablet (generic Tricor)			
2. Does the Beneficiary have a contraindication or intolerance to any of the preferred agents listed in question (1)?			<input type="checkbox"/> Yes – Submit medical record documentation of contraindications/intolerances. <input type="checkbox"/> No

PLEASE FAX COMPLETED FORM WITH SUPPORTING CLINICAL DOCUMENTATION TO DHS – PHARMACY DIVISION

Prescriber Signature:	Date:
-----------------------	-------

Confidentiality Notice: The documents accompanying this telecopy may contain confidential information belonging to the sender. The information is intended only for the use of the individual named above. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or taking of any telecopy is strictly prohibited.